Mutant protein in Huntington disease is resistant to proteolysis in affected brain

Nature Genetics

Volumn 29, Issue 3, 2001, Pages 270-278

  Dyer, Roy B ^a   McMurray, Cynthia T ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; MUTANT PROTEIN; POLYGLUTAMINE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BRAIN REGION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; HUNTINGTON CHOREA; MOUSE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION;

AGED; ANIMALS; BRAIN; CASPASE 3; CASPASES; CELL DEATH; CELL LINE; CHROMATOGRAPHY, GEL; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MIDDLE AGED; MODELS, BIOLOGICAL; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; ORGAN SPECIFICITY; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY; SOLUBILITY; TRINUCLEOTIDE REPEAT EXPANSION;

ANIMALIA;

EID: 0035179456     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/ng745     Document Type: Article

References (48)

1. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract
2. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract
3. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology
4. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity
5. Intranuclear neuronal inclusions: A common pathogenic mechanism for glutamine-repeat neurodegeneration disease?
6. Nuclear inclusions in glutamine repeat disorders: Are they pernicious, coincidental, or beneficial?
7. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain
8. Tissue-specific proteolysis of huntingtin (htt) in human brain: Evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum
9. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture
10. The influence of huntingtin protein size on nuclear localization and toxicity
11. Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats
12. A cellular model that recapitulates major pathogenic steps of Huntington's disease
13. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates
14. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions
15. In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease
16. Mutant huntingtin expression in clonal striatal cells: Dissociation of inclusion formation and neuronal survival by caspase inhibition
17. Caspase-8 is required for cell death induced by expanded polyglutamine repeats
18. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
19. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin
20. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease
21. Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice
22. Huntingtin aggregates may not predict neuronal death in Huntington's disease
23. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells
24. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease
25. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice
26. Huntingtin-encoded polyglutamine expansions form amyloid-like aggregates in vitro and in vivo
27. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: Implications for Huntington's disease pathology
28. Formic acid dissolves aggregates of an N-terminal huntingtin fragment containing an expanded polyglutamine tract: Applying to quantification of protein components of the aggregates
29. Differential loss of striatal projection neurons in Huntington's disease
30. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease
31. Huntington disease
32. CAG expansion affects the expression of mutant huntingtin in the Huntington's disease brain
33. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form
34. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias
35. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein
36. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: Correlation between the density of inclusions and IT1S CAG triplet repeat length
37. Q111 knock-in mice
38. Widespread expression of Huntington's disease gene (IT15) protein product
39. The Huntington's disease protein interacts with p53 and CRE8-binding protein and represses transcription
40. Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity
41. A molecular investigation of true dominance in Huntington's disease
42. Polyglutamine-mediated aggregation and cell death
43. Amyloid formation by mutant huntingtin: Threshold, progressivity, and recruitment of normal polyglutamine proteins
44. Inactivation of Hdh in the brain and testis result in progressive neurodegeneration and sterility in mice
45. Different mechanisms underlie DNA instability in Huntington disease and colorectal cancer
46. Trinucleotide expansion in haploid germ cells by gap repair
47. Regulated expression of the prodynorphin gene in the R2C Leydig tumor cell line
48. Neuropathological classification of Huntington's disease